Kornimate/medical-research-clean huggingface dataset:
investigation of the effects of kinesio taping and manual therapy in patients with bruxism

Conditions: Bruxism

Summary: bruxism is defined as a repetitive jaw-muscle activity characterized by tooth grinding or clenching accompanied with wearing of the teeth, and jaw muscle discomfort in the absence of a medical disorder . bruxism has two distinct circadian manifestations: it can be nocturnal or diurnal. hypertrophy of the masseter muscle is an objective sign of bruxism. additionally, fatigue or stiffness in the masticatory muscles, pain in the temporomandibular joint or headaches are subjective signs of bruxism. according to literature, 85% to 90% of the general population experience episodes of bruxism during their lives. thus, finding an effective treatment method for bruxism is crucial.the aim of this study is to investigate the effects of two different physiotherapy approaches on the masseter muscle thickness and stiffness in patients with bruxism.

there is no certain treatment for bruxism. however, the most recent recommendation is to follow the multiple-p approach prior to medical drug regimens and invasive procedures. different methods used in the conservative management of bruxism are known as the "multiple-p" approach, which consists of; physiotherapy, plates, pep talk, pills and psychology . physiotherapy generally focuses on two objectives: decreasing the adverse effects of bruxism to the masticatory muscles and increasing self-awareness regarding this habit. these studies involve different intervention such as massage of the masticatory and cervical muscles, electrotherapy, therapeutic exercises, taping interventions or relaxation therapies . however, literature regarding which physiotherapy intervention is the most effective in bruxism is not clear. therefore patients in this study were randomly divided into one of two groups; manual therapy or kinesio taping. all patients were assessed at baseline, received 4 weeks of treatment and were assessed following the 4 weeks.

Eligibility criteria:
inclusion criteria: * a bruxism diagnosis according to the criteria of the international classification for sleep disorders * self-report of awake bruxism exclusion criteria: * having more than 2 missing teeth * the presence of removable partial dentures * having neurological, psychiatric or motor disorders * having any ongoing dental or physical therapy * active cancer

Keywords: bruxism manual therapy kinesio taping physiotherapy
a multicenter, randomized, double-blind, placebo-controlled phase 3 study to evaluate the safety and efficacy of es135 in subjects with spinal cord injury

Conditions: Spinal Cord Injuries

Summary: to demonstrate the superior effect of es135 combined with spinal cord repairing surgery, compared to a placebo control with spinal cord repairing surgery, on post-surgery motor function recovery as measured by the changes from baseline of isncsci motor scores in subjects


Eligibility criteria:
inclusion criteria: 1. subjects of either sex and 15-65 years of age. 2. subjects have spinal cord injury and the subjects must be categorized as grade a or b by the asia impairment scale. 3. subjects have adequate heart, lung, kidney and liver function. 4. subjects are able to give voluntary and dated informed consent prior to enrollment. exclusion criteria 1. penetration sci 2. brain damage or multiple injuries 3. history of congenital or acquired abnormalities in the spinal cavity 4. history of congenital or acquired immunodeficiency disorders 5. history of malignancies or positive results 6. current serious/uncontrollable infections or others serious diseases 7. pregnant or lactating women 8. allergy to es135 or any of its excipients 9. unable to obtain informed consent from subject

Keywords: spinal cord, spinal cord injury
evidence-based screening strategies for celiac disease

Conditions: Celiac Disease

Summary: main aim: to find evidence-based screening strategies for celiac disease in high risk groups and to find new biomarkers or biomarker combinations for celiac disease diagnostics and follow-up.

the current project will result in the identification of genetic, environmental or downstream biomedical markers that predict the development of celiac disease at the individual level. moreover, the markers can be exploited in prediction of specific disease risks, manifestations, comorbidities and complications.

Eligibility criteria:
inclusion criteria: * cohort 1: family member of celiac disease patient * cohort 2: previously diagnosed celiac disease exclusion criteria: * cohort 1: no previous celiac disease * cohort 2: celiac disease diagnosis not confirmed

Keywords: celiac disease, gluten, microbiome, genetic
a phase 3 study to evaluate efficacy and safety of masitinib in patients with relapse or refractory multiple myeloma

Conditions: Multiple Myeloma

Summary: the purpose of the study is to compare the efficacy and safety of masitinib 6 mg/kg/day in combination with bortezomib and dexamethasone to placebo in combination with bortezomib and dexamethasone in the treatment of patients with relapsing multiple myeloma who have received one previous therapy.

this is a prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel group, phase 3 study to compare efficacy and safety of masitinib 9 mg/kg/day to placebo in the treatment of patients with relapsing multiple myeloma who received one previous therapy. patients will receive study treatment (masitinib/placebo) with the standard therapy (bortezomib and dexamethazone).

Eligibility criteria:
inclusion criteria: 1. patient with confirmed multiple myeloma requiring systemic therapy. a 2. patient with multiple myeloma relapsing according to the international uniform response criteria for multiple myeloma (imwg 2009/ revised bladé criteria) to one previous line of treatment 3. patient with measurable progressive disease exclusion criteria: 1. patient with peripheral neuropathy grade \>2 2. patient with hypersensitivity to bortezomib, boron or dexamethasone 3. patient whose disease progressed during or within 60 days of bortezomib treatment or of any other multiple myeloma therapy 4. patient who received bortezomib within 6 months of randomization to this study 5. past discontinuation of bortezomib due to associated grade 3 or higher adverse event 6. patient with contra-indication to high dose of steroids (including ongoing active infection, use of live vaccines, virosis such as hepatitis, herpes, varicella, herpes zoster)

Keywords: multiple myeloma relapse second line therapy bortezomib dexamethasone
upper airway physical therapy for the treatment of obstructive sleep apnea

Conditions: Obstructive Sleep Apnea Syndrome

Summary: the purpose of this study is to determine the effectiveness and feasibility of upper airway muscle physical therapy utilizing negative airway pressure (nap) breathing training in patients with obstructive sleep apnea syndrome (osas) in reducing both signs (apnea hypopnea index) and symptoms (i.e., daytime sleepiness).the key to the proposed therapy is the use of negative air pressure when awake so that the increased reflex phasic drive to the muscles will result in muscle conditioning. interestingly, other studies have indicated that upper airway muscle training may be useful in treating osas, but these studies used techniques that were not scientifically designed{puhan, 2006 8195 /id} or used a technique (electrical stimulation) that was not well tolerated.{lequeux, 2005 7514 /id}

overview: subjects with osas (but not using continuous positive airway pressure cpap) will undergo nap physical therapy of the upper airway, utilizing a physiologically determined training pressure and protocol, three days a week (approximately 30 minute sessions each) for a period of three months. overnight sleep studies (psgs) will be performed pre- and post-study. primary outcome measurements include the pre- and post-study apnea/hypopnea index (ahi) and daytime hypersomnolence symptom scores. each subject's total study time is approximately a 3-4 month period which includes screening visit, pre and post study overnight polysomnography, and therapy sessions of 3-4 a week for three months.

Eligibility criteria:
inclusion criteria: 18 and over and any persons who have been diagnosed with osas (ahi over 15) and who are not utilizing cpap exclusion criteria: participants will be excluded if: pregnant, breastfeeding or any bleeding abnormalities, there is a major upper airway morphologic abnormality (e.g., retrognathia, pierre-robin syndrome), they have had any airway surgery (except tonsillectomy as a child),they regularly use any drugs that are known to depress the central nervous system (such as benzodiazepines, narcotics), they consume 14 alcoholic drinks a week or 2 a day,they are undergoing a current or planned intervention for weight reduction or are morbidly obese (body mass index 40 kg/m2), or they have any unstable medical or psychiatric illnesses.

Keywords: obstructive sleep apnea syndrome (osas) sleep apnea
stroke patients' preferences for an exoskeleton for lower limb rehabilitation using the dce method (exopref)

Conditions: Chronic Stroke Patients

Summary: the main aim of this study is to investigate the preferences of individual stroke patients for key features of an exoskeleton, intended for lower limb rehabilitation, with a view to its potential integration into the design of future exoskeletons. this will be a multicenter study. patients will be presented different scenarios of choices about the attributes about gait exoskeleton. conditional logistic regression models will be used to define the preferences of the subjects.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * informed consent to participate in the study * motor impairment secondary to stroke * ability to answer the questionnaire with or without assistance from a relative or interviewer exclusion criteria: - history of lower-limb exoskeleton use
open label study to assess the effect of secukinumab in moderate to severe papulopustular rosacea

Conditions: Papulopustular Rosacea

Summary: this is a study to determine whether secukinumab is a potential therapy for those with papulopustular rosacea. we will observe whether this drug decreases the size and/or amount and severity of the pustules of those who suffer from rosacea.

rosacea is a common inflammatory skin disease affecting up to 10% of adults. despite this, the etiology of rosacea is unclear, although there may be a genetic predisposition (chang et al., 2015). currently, there is no cure. rosacea can lead to scarring, itching, burning, and is associated with anxiety and depression (moustafa et al., 2015), significantly affecting quality of life. secukinumab is an antibody that binds to a protein (interleukin (il)-17a) that is involved in inflammation. when il-17a is bound to secukinumab, it cannot bind to its receptor, thereby inhibiting its ability to feed the inflammatory response. in clinical trials, secukinumab has been effective for moderate to severe psoriasis (blauvelt et al., 2015). recently, human data from all types of rosacea have shown th1/th17 polarization profile of the t-cell response, suggesting that anti-il-17 therapy may be beneficial for rosacea (buhl et al., 2015). hence, secukinumab could be effective against rosacea. this proposal is a proof-of-concept study to use secukinumab in open label design for moderate to severe papulopustular rosacea.

Eligibility criteria:
inclusion criteria: * moderate to severe papulopustular rosacea defined clinically using the grading system of wilkin et al. (2004) as having at least ten lesions (either papules or pustules) on face at time of enrollment * age 18 years or greater willing and able to understand and sign informed consent form exclusion criteria: * known hypersensitivity to secukinumab * topical or oral anti-rosacea medication usage for 28 days prior to enrollment * active crohn's disease, as secukinumab may exacerbate this disease * active infection including tuberculosis, hepatitis b or c, human immunodeficiency virus * participants with latent tuberculosis will need to have treatment initiated prior to starting study drug * pregnant or lactating * active and/or uncontrolled medical conditions that may interfere with study procedures or obscure rosacea assessment such as cutaneous lupus * use of retinoids within past 3 months of enrollment * use of antibiotics within 4 weeks of enrollment * use of light based or laser treatment to face within 8 weeks of enrollment * use of topical or systemic steroids within 4 weeks of enrollment * acne conglobate, acne fulminans, chloracne, severe acne requiring systemic treatment
management of tubo-ovarian abscess: a single center experience

Conditions: Tubo-ovarian Abscess

Summary: electronic database of our tertiary obstetrics and gynecology clinic was searched for patients who were treated for tub-ovarian abscess during the last 10 years (january 2010- november 2020). patients' biometric data, admission date and duration, medical and surgical treatment modalities were recorded using an excel sheet. patients will be evaluated on the basis of the treatment they receive, length of treatment, if surgically treatment the type of surgery performed. hospitalization length, readmission, recurrence will be compared between treatment modalities.

this retrospective study is conducted at health sciences university turkey, sisli hamidiye etfal training and research hospital department of obstetrics and gynecology. electronic database was searched for patients who were treated for tub-ovarian abscess during the last 10 years (january 2010- november 2020). patients' biometric data, admission date and duration, medical and surgical treatment modalities were recorded using an excel sheet. patients will be evaluated on the basis of the treatment they receive, length of treatment, if surgically treatment the type of surgery performed. hospitalization length, readmission, recurrence will be compared between treatment modalities. a change in management strategy over the years if any will be reported.

Eligibility criteria:
inclusion criteria: * presence of a pelvic mass \> 3 cm with transvaginal ultrasound or magnetic resonance imaging indication abscess * cervical and uterine tenderness * abdominal rebound-defense under physical examination indication peritoneal irritation * presence of symptoms such as fever, pelvic pain and increase in laboratory infection parameters exclusion criteria: * patients with known malignities * patients with incomplete data in the clinic's electronic database * patients who continued their treatment at other centers

Keywords: abscess drainage abscess size medical treatment surgical treatment
efficacy & safety of loratadine-betamethasone oral solution for treatment of severe perennial allergic rhinitis in children (study p03428)

Conditions: Rhinitis

Summary: this study attempts to document the therapeutic value of combining loratadine antihistamine action (no sedative) with anti-inflammatory effects of betamethasone at low doses, which may facilitate treatment adherence by patients whereas providing an effective and rapid perennial allergic rhinitis (par) symptoms relief.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of perennial allergic rhinitis. * age \>= 6 years old and \<= 12 years old. * patients in good general conditions, without any other relevant clinical condition except for perennial allergic rhinitis. * symptoms total score at admission \>= 8 (out of 15 possible). individual symptoms (score 0 to 3 points) were: sneezing or nasal pruritus, eye reddening or pruritus, nasal congestion, wet nose or with secretion (sniffing), secretion sensation at pharynx (post-nasal dripping). * number of symptoms: at least three. exclusion criteria: * age \ 12 years old. * co-existence of acute sinusitis or some chronic condition different from asthma or atopic dermatitis. * presence of systemic fungal infections. * conscience or behavioral disturbances. * current oral or parenteral steroid treatment. * concomitant use of phenobarbital, rifampicin, diphenylhydantoin or ephedrine. * known hypersensitivity to any of the study pharmacological combination components.
urdutranslation and validation of the pelvic floor distress inventory short form (pfdi-20)

Conditions: Pelvic Floor Disorders

Summary: to translate and culturally adapt pelvic floor distress inventory short form (pfdi-20) into urdu and to evaluate the reliability and validity of urdu version of pelvic floor distress inventory (short form).urdu is the national language of pakistan. the pfdi-20 has not been translated into urdu so far. in order to use in urdu speaking people, it is necessary to translate and culturally adapt pfdi-20 into urdu language, so that it can be better understood by this population.

pelvic floor disorders, which include urinary incontinence, fecal incontinence, and pelvic organ prolapse, are highly prevalent conditions in women, affecting overall, almost 25% of women in the united states because there are different types of pelvic floor disorders (pfds), symptoms of different pfds can vary or overlap. for example, women with pfds may feel: heaviness, fullness, pulling, or aching in the vagina that gets worse by the end of the day or is related to a bowel movement; see or feel a "bulge" or "something coming out" of the vagina, have difficulty starting to urinate or emptying the bladder completely, leak urine when coughing, laughing, or exercising, feel an urgent or frequent need to urinate, feel pain while urinating, leak stool or have difficulty controlling gas, have constipation and have difficulty making it to the bathroom in time pfdi-20 has been translated into many languages across the globe to check the validity, reliability and responsiveness of the scale, in their native languages. a study was conducted to assess validity of pfdi-20 in finnish by using multistep translation method with sample size of 63, they found it a valid tool. in turkish language validity and reliability of this tool was addressed on larger number of women and was recommended as valid and reliable tool

Eligibility criteria:
inclusion criteria: * menopausal women aged 45 years and older, those who can read and understand urdu language exclusion criteria: * previous pelvic surgery, malignant tumor, cognitive impairment and dementia

Keywords: pelvic floor distress inventory pelvic floor disorders postmenupausal women
a phase 2 extension study of study gcs-100-cs-4002

Conditions: Chronic Kidney Disease

Summary: the primary objective of this study is to determine the safety and tolerability of extended dosing of gcs-100 in patients with ckd.

galectin-3 contributes to fibrosis, is elevated in patients with esrd, and correlates with adverse outcomes. animal models with genetic knockout of galectin-3 demonstrate a reduction in structural and functional deficits in the kidney. gcs-100 is a galectin-3 antagonist that has been shown to reduce fibrosis pre-clinically. based on the role of galectin-3 and fibrosis in kidney disease, the sponsor believes gcs-100 may be effective at treating patients with ckd. study gcs-100-cs-4002 is an ongoing randomized, placebo controlled study of gcs-100 in stage 3b and 4 ckd. the objective of the study is to determine the safety and efficacy of 8 weekly injections of gcs-100 on egfr. patients who have completed that study without adverse safety events, may be asked to participate in this study to test the safety of prolonged administration of study drug.

Eligibility criteria:
inclusion criteria: 1. subject is capable of understanding the purpose and risks of the study and is able to provide written informed consent 2. subject was enrolled in and completed the end of study (day 85) of gcs-100-cs-4002 exclusion criteria: 1. subject experienced a grade 3 or worse adverse event related to gcs-100 in clinical study gcs-100-cs-4002 2. systolic blood pressure ≤90 mmhg and ≥160 mmhg and diastolic blood pressure ≤40 mmhg and ≤100 mmhg at screening 3. subject has clinical laboratory results of: 1. hemoglobin: ≤9g/dl 2. total bilirubin: \>1.5x the upper limit of normal (uln) 3. alt and/or ast: \>2.5x uln 4. subject has a concomitant disease or condition, including laboratory abnormalities, which, in the opinion of the investigator, could interfere with the conduct of the study or put the subject at unacceptable risk 5. subject who may require renal replacement therapy within the next 2 months, at the discretion of the investigator
a single-dose study to assess the pharmacokinetics of cabozantinib (xl184) capsules in subjects with impaired renal function

Conditions: Healthy; Renal Impairment

Summary: the main objective of the trial is to compare the pharmacokinetics of a 60 mg dose of cabozantinib in adult subjects with impaired renal function compared with healthy adult subjects. another objective is to assess the safety and tolerability of cabozantinib in these adult subjects.


Eligibility criteria:
inclusion criteria: * body weight must be ≥ 50 kg and \< 130 kg with a bmi ≤ 38.0 (kg/m2). * must use acceptable form of birth control during the course of the study and for 3 months following the single dose of study drug. * female subjects of childbearing potential must have a negative pregnancy test at screening and check-in. * negative test for hiv; hepatitis a, b, and c. * must have adequate vital sign reads at screening and check-in. * must be able to comply with dietary and fluid restrictions required for the study. exclusion criteria: * history of medical or surgical conditions that would interfere with gi absorption, distribution, metabolism, or excretion of the study drug. * recent clinical evidence of pancreatic injury. * recent use of drugs known to significantly inhibit or induce p450 cyp3a4 enzymes. * previous diagnosis of malignancy. * unwilling to forgo use of any over-the-counter or non-prescription preparations.
metabolic effects of four-week lactate-ketone ester supplementation

Conditions: Obesity

Summary: recent research reveals intriguing results concerning the role of exogenous lactate and the ketone body 3-hydroxybutyrate (3-ohb) as therapeutic tools to combat obesity and related conditions. thus, oral administration of lactate and 3-ohb have separately been shown to suppress appetite sensations and slow gastric emptying while administered orally. both seem to inhibit lipolysis while oral 3-ohb administration have shown direct insulin sensitizing effects. furthermore, both substrates can be used as fuel for the heart. the goal of this placebo-controlled randomized crossover design is to test exogenous lactate and the ketone body 3-hydroxybutyrate (3-ohb) in healthy, non-diabetic, obese adults. the main questions it aims to answer are if chronic administration of lake ester affect or improve the following endpoints: * insulin sensitivity * appetite sensations * gastric emptying * lipolysis * cardiac output * left ventricular ejection fraction * global longitudinal strain and other echocardiographic measures listed below participants will ingest a combined lactate and ketone body ester (lake ester) or placebo twice a day for 28 days before experimental days.


Eligibility criteria:
inclusion criteria: * age between 30-60 years * bmi range 30-40 * glycated haemoglobin (hba1c) \< 48 mmol/mol * otherwise 'healthy' * written and oral consent exclusion criteria: * medication that affect energy or glucose metabolism, eg metformin, insulin or glucagon-like peptide-1 receptor (glp-1) agonists * specific diets (eg practicing ketogenic diets) * cardiac arrhythmias (eg atrial fibrillation) * ongoing acute/chronic serious diseases (eg, anemia, chronic kidney or liver disease) * inability to understand danish or english

Keywords: insulin sensitivity lipolysis appetite